Cryosite Hisse

Cryosite EBITDA

Cryosite (CTE.AX) öğesinin EBITDA (Faiz, Vergi, Amortisman Öncesi Kâr) değeri 19 Ağu 2026 itibarıyla 3,37 M AUD dir. Önceki yılda, EBITDA (Faiz, Vergi, Amortisman Öncesi Kâr) 2,84 M AUD idi — 18,51% (daha yüksek) bir değişiklik.

EBITDA

3,37 MAUD

YoY

18,51%

Son güncelleme:

Cryosite öğesinin EBITDA (Faiz, Vergi, Amortisman Öncesi Kâr) değeri 2026 3,37 M AUD dir. Cryosite öğesinin EBITDA (Faiz, Vergi, Amortisman Öncesi Kâr) değeri 2025 2,84 M AUD idi. %18,51 daha yüksek önceki yıla kıyasla azalmaktadır.
Access this data via the Eulerpool API

Cryosite Hisse senedi analizi

Cryosite ne yapar? Cryosite Ltd was founded in Australia in 1999 and has since become a leading provider of services in the field of biological sample storage. The company specializes in the storage of blood, bone marrow, tissue, and other biological samples. Based in Sydney, Cryosite Ltd operates branches throughout Australia and is increasingly expanding into international business. Cryosite Ltd's business model is based on providing secure and reliable storage solutions for biological samples. This includes the collection, processing, and storage of biological samples, as well as their transportation and traceability. Cryosite Ltd offers its customers a comprehensive range of services to facilitate the storage and shipment of biological samples. This includes the development of customized archiving solutions tailored to individual needs. The company's various divisions include archiving solutions, clinical trials, stem cell therapy, biobanking, and blood banks. Cryosite Ltd's archiving solutions involve the setup, maintenance, and monitoring of biological samples in engraved tubes and boxes. The company offers a variety of cryopreservation systems to ensure that samples are stored under optimal conditions and can be retrieved within a specified timeframe. Additionally, the company also provides digital archiving solutions that enable efficient management and retrieval of stored data. Cryosite Ltd is also involved in clinical trials by assisting companies in conducting clinical studies. The company provides the necessary logistics and sample management to ensure that samples are properly processed, stored, and returned. It also provides comprehensive documentation to ensure the highest compliance standards. In the field of stem cell therapy, Cryosite Ltd offers a wide range of services that enable companies and researchers to store and process stem cells under optimal conditions. The company specializes in providing a wide range of application-oriented solutions and is a leader in the industry in supporting customers in the use of these technologies to enhance diagnostic and therapeutic discoveries. In the field of biobanking, Cryosite Ltd offers a comprehensive range of services to research institutes and organizations. Biobanking services include the setup, storage, monitoring, and tracking of biological samples for future research purposes. The company also offers services for the biobanking of clinical samples for disease diagnosis and evaluation. The company also operates blood banks that focus on blood donation and storage of blood products for efficient availability to patients. It offers a wide range of blood bank products and services to ensure effective blood supply for patients. Cryosite Ltd is committed to providing its customers with the highest standards in the storage and handling of blood products. In summary, Cryosite Ltd is a leading provider of storage and processing services for biological samples. The company has a long history of providing solutions for a wide range of applications in medical research and the medical industry. It strives to meet the highest standards and ensure that all samples are processed and stored efficiently and safely. Cryosite Ltd stays up to date with the latest technology and advanced processes to handle samples with maximum efficiency and quality. Cryosite, Eulerpool'daki en popüler şirketlerden biridir.

Cryosite hisse senedi hakkında sık sorulan sorular

Cryosite şirketinin EBITDA (Faiz, Vergi, Amortisman Öncesi Kâr) değeri 2026 yılında 3,37 M AUD.

Cryosite öğesinin EBITDA (Faiz, Vergi, Amortisman Öncesi Kâr) değeri 2,84 M AUD değerinden 3,37 M AUD değerine değişmiş ve bu %18,51 değişimi temsil etmektedir. Değer önceki yıldan daha yüksek dir.

Eulerpool'da EBITDA (Faiz, Vergi, Amortisman Öncesi Kâr) öğesinin Cryosite değerinin 2006'dan itibaren tam tarihsel gelişimini bulabilirsiniz — yıllık değerler, grafikler ve ayrıntılı analiz ile.

EBITDA, finansal yapı, vergi ortamı ve nakit olmayan amortisman giderleri etkisinden önceki işletme performansını ölçer.

EBITDA = EBIT + Amortisman

EBITDA (Faiz, Vergi, Amortisman Öncesi Kâr)'nin AUD, yatırımcılar için kilit bir faktördür. Bu metrikte yapılan değişiklikler temel faktörlerin iyileşmesini veya kötüleşmesini gösterebilir ve hisse senedi fiyatını doğrudan etkiler. Eulerpool'da EBITDA (Faiz, Vergi, Amortisman Öncesi Kâr)'nin Cryosite değerini tarihsel olarak ve gerçek zamanlı olarak takip edebilirsiniz.

Access this data via the Eulerpool API

Gelir Tablosu — Cryosite

Tüm Kilit Metrikler — Cryosite